Not applicableLooking for participantsNCT05298722
What this trial is testing
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
Who this might be right for
Pancreatic Cancer
University Hospital, Ghent 45